Pyramid Biosciences Announces Exclusive Global License of AstraZeneca TRK Program for Dermatology and Inflammatory Diseases

Author's Avatar
Dec 17, 2018
Article's Main Image

- Pyramid Biosciences to exclusively develop AstraZeneca's novel cell surface receptor (TRK) program

- Targeting range of dermatological and inflammatory diseases, including psoriasis and atopic dermatitis

- Pyramid Biosciences Inc. will develop and commercialize potential therapies globally

PR Newswire